Navellier & Associates Inc Jounce Therapeutics, Inc. Transaction History

Navellier & Associates Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 29, 2022	SELL	$6.01 - $8.54 $147,912 - $210,177	-24,611 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $92,394 - $125,271	12,995 Added 111.87%	24,611 $206,000
Q3 2021 Oct 28, 2021	SELL	$5.04 - $8.73 $2,273 - $3,937	-451 Reduced 3.74%	11,616 $86,000
Q2 2021 Aug 09, 2021	SELL	$6.58 - $10.66 $605 - $980	-92 Reduced 0.76%	12,067 $82,000
Q4 2020 Feb 05, 2021	SELL	$6.37 - $10.33 $4,185 - $6,786	-657 Reduced 5.13%	12,159 $85,000
Q3 2020 Nov 09, 2020	BUY	$4.58 - $10.95 $732 - $1,752	160 Added 1.26%	12,816 $105,000
Q2 2020 Aug 12, 2020	BUY	$4.17 - $7.58 $52,775 - $95,932	12,656 New	12,656 $87,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Navellier & Associates Inc, based on Form 13F filings with the SEC.

Stay updated on Navellier & Associates Inc with notifications on news.